| Document |
Document Title |
|
WO/2022/237689A1 |
Provided in the present disclosure is a method for preparing dihydroquercetin, which belongs to the field of pharmaceutical synthesis. The method comprises the following steps: adjusting reaction solvent water to be alkaline with an alka...
|
|
WO/2022/237690A1 |
The present disclosure provides a semi-synthetic method for dihydroquercetin, which belongs to the field of organic and pharmaceutical synthesis. The semi-synthetic method comprises the following steps: adjusting solvent water to be alka...
|
|
WO/2022/238592A2 |
The present invention relates to a novel photoinitiator having improved performances and to its use in photopolymerization compositions. The invention also relates to a process for the photopolymerization of compositions comprising said ...
|
|
WO/2022/232948A1 |
The present application includes processes for preparing the (R)- or (S)-enantiomers of 3,4-methylenedioxymethamphetamine (MDMA) and the (R)- or (S)-enantiomers of N-methyl-1,3-benzodioxolylbutanamine (MBDB) starting with the alkyl ester...
|
|
WO/2022/232940A1 |
The present disclosure relates to hashish products and processes for manufacturing same. The processes comprise pressing isolated cannabis trichomes that contain a cannabis oil layer on at least a portion of a surface thereof, to obtain ...
|
|
WO/2022/235574A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3 -kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I) or pharmaceutically...
|
|
WO/2022/232897A1 |
Liposomal polyphenol compositions comprised of lipophilic glycoside free flavonoids and cannabinoids, each separately and optimally encapsulated within membrane lipid bilayers of mostly spherical vesicles, their methods of preparation an...
|
|
WO/2022/233428A1 |
A method for synthesizing xanthohumol (XN) from naringenin comprising steps of acylating hydroxyl groups of a naringenin flavone moiety to obtain an acylation product, a reaction of conversion of the flavone moiety into a chalcone moiety...
|
|
WO/2022/233919A2 |
The disclosed and claimed subject matter relates to spin-on metal-organic formulations that include zirconium.
|
|
WO/2022/232905A1 |
The present disclosure relates to industrial hashish products and industrial process for manufacturing same. The process comprises mixing isolated cannabis trichomes while adding mechanical or thermal energy under conditions sufficient t...
|
|
WO/2022/232694A1 |
Disclosed are small molecule PTPRD inhibitors and uses thereof. Methods of using the PTPRD inhibitors include methods of treating, preventing, or delaying the progression of a disorder responsive to PTPRD inhibition, including for exampl...
|
|
WO/2022/229214A1 |
The present invention relates to the formation of compound of the formula (I) by a ring closure reaction of the compound of the formula (II) in the presence of a base in a two-phase system. It has been found that this reaction is very ef...
|
|
WO/2022/229213A1 |
The present invention relates to the formation of compound of the formula (I) by reacting 2,3,6-trimethylhydroquinone or a protected derivative thereof with the unsaturated alcohol of formula (IIIa) or (IIIb) in the presence of Gd(OTf)3 ...
|
|
WO/2022/229417A1 |
The present invention concerns compounds of Formula (1), pharmaceutically acceptable salts, solvates or prodrugs thereof, pharmaceutical compositions comprising the same, and the use of the same in treating or preventing a disease.
|
|
WO/2022/226639A1 |
The present disclosure addresses the need to obtain cannabinoid emulsification systems that are capable of generating controllable, stable small particle size for making cannabis-infused products. The disclosure relates to self-emulsifyi...
|
|
WO/2022/229215A1 |
The present invention relates to the formation of compound of the formula (I) by a ring closure reaction of the compound of the formula (II) in the presence of a catalytic amounts of a base. It has been found that this reaction is very e...
|
|
WO/2022/221968A1 |
The present invention relates to compositions and methods for controlling infections in plant crops, comprising the application of metabolites to crops infected with various microorganisms, such as microorganisms of the genus Pseudomonas...
|
|
WO/2022/224184A1 |
The present disclosure relates to the to the transdermal administration of active agents, such as diclofenac and/or CBD and/or THC, and derivatives of these compounds, for the treatment and/or prevention and/or control of chronic pain.
|
|
WO/2022/221348A1 |
Embodiments provided for herein related to pomace leachate, such as being used as a herbicide. In some embodiments, the herbicide comprises a seed extract, concentrated pomace leachate, a diluent or some combination thereof. Embodiments ...
|
|
WO/2022/217367A1 |
The present disclosure relates to hashish products and processes for manufacturing same. The processes comprise pressing partly decarboxylated isolated cannabis trichomes to obtain a cohesive mass of isolated cannabis trichomes. The hash...
|
|
WO/2022/220163A1 |
[Problem] To provide, according to the present invention, a novel compound that binds specifically to an intracellular and/or extracellular vesicle, a mitochondria staining agent, and a method for fluorescent staining of mitochondria. Th...
|
|
WO/2022/148752A9 |
The present disclosure relates to a photochromic molecule and uses of said molecule. The present disclosure further relates to a method of preparing a film comprising said molecule. The present disclosure also relates to a film prepared ...
|
|
WO/2022/213880A1 |
The present invention relates to a method for separating and purifying tetrahydrocannabivarin (THCV) by means of high-speed countercurrent chromatography, the method comprising: sufficiently shaking a solvent system, leaving same to stan...
|
|
WO/2022/217248A1 |
Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating neurological disorders. For example, provided herein is a compound of Formula I: or a pharmaceutically acceptable salt ...
|
|
WO/2022/217247A1 |
Disclosed are isochromane and related compounds, and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
|
|
WO/2022/217232A1 |
Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating a neurological or psychiatric disease or disorder. For example, provided herein is a compound of Formula I: (I) or a ph...
|
|
WO/2022/204811A1 |
The present application relates to water-soluble formulations. More specifically, the present application relates to formulations comprising at least one of Coenzyme-Q10 and an ashwagandha root extract and a solubilizing agent. More spec...
|
|
WO/2022/206422A1 |
The present invention relates to a compound represented by formula (I). The compound is suitable for use in electronic components, in particular, suitable for use in organic electroluminescent elements. The present invention also relates...
|
|
WO/2022/200541A1 |
The present invention relates to chromen-4-one derivatives, and to associated salts, multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the...
|
|
WO/2022/201603A1 |
Provided are indeno-fused naphthopyran compound particles having a crystallinity of 60.00% or more and a maximum melting rate of 25% or less at a temperature of 200°C or less in a melting curve.
|
|
WO/2022/201602A1 |
Provided are indeno-fused naphthopyran compound particles having a crystallinity of 10.00% or less and a maximum primary particle size of 200 μm or less.
|
|
WO/2022/204451A1 |
A cannabis conversion method includes providing a starting material that includes cannabidiol (CBD), combining the starting material with a solvent and a Lewis acid to form a mixture, the solvent and the Lewis acid reacting with the CBD ...
|
|
WO/2022/187935A1 |
Cannabinol (CBN) is a minor cannabinoid found in the cannabis plant and there is significant interest in exploring CBN for pharmaceutical applications. It is currently being investigated for treating glaucoma, sleep disorders and skin in...
|
|
WO/2022/189945A1 |
Topical compositions comprising cannabinoids in combination with one or more humectants and one or more penetration enhancers are provided. Also provided are methods comprising applying a topical cannabinoid composition provided herein t...
|
|
WO/2022/187973A1 |
The present invention discloses compositions from mushrooms and cannabis, including with synergistic and entourage enhanced combinations of psilocybin and other psychoactive tryptamines, THC, CBD, and other cannabinoids, and other active...
|
|
WO/2022/183908A1 |
An industrial method for continuously extracting a high-content marigold flavonoid and a marigold flavonoid product obtained thereby. The method comprises the following steps: 1) granulating a marigold flower raw material, a ring mold co...
|
|
WO/2022/156615A9 |
The present invention relates to a preparation method for a non-ester-type tea polyphenol rich in EGC, the method comprising: subjecting crushed and wall-broken tea leaves to enzymatic hydrolysis by using endogenous hydrolase at the cont...
|
|
WO/2022/182973A1 |
Provided herein are methods for converting CBD to a product mixture comprising Δ8-THC, Δ9-THC, or a combination thereof. The methods provided herein may comprise one or more of (1) a contacting step wherein a starting material comprisi...
|
|
WO/2022/183223A1 |
A method is provided for marking a petroleum fuel or other carbonaceous fluid with a marker or tracer. The method may include introducing the marker into the fluid. The marker may be a substance that is extractable from a plant (includin...
|
|
WO/2022/182962A1 |
Provided herein are methods for converting CBD to a product mixture comprising Δ8-THC, Δ9-THC, or a combination thereof. The methods provided herein may comprise one or more of (1) a contacting step wherein a starting material comprisi...
|
|
WO/2022/178967A1 |
The present invention relates to a pharmaceutical composition, comprising two components: the first component is selected from forskolin, isoforskolin, or a pharmaceutically acceptable salt thereof; the second component is selected from ...
|
|
WO/2022/182843A1 |
Proanthocyanidin-cinnamaldehydes pyrylium products (FP) were synthesized by the condensation reaction of proanthocyanidins (PAC) with various cinnamaldehydes. Synthesized FP exhibited fluorescence at higher excitation and emission wavele...
|
|
WO/2022/175660A1 |
There are provided compounds of formula (I): [hyaluronan production inhibitor]—[labile linker]—X (I), which compounds are useful in the treatment of diseases associated with hyaluronan overproduction.
|
|
WO/2022/175907A1 |
The present disclosure provides novel coumarin compounds of formula (I), a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof and pharmaceutical compositions comprising them. The...
|
|
WO/2022/178527A1 |
Provided here are compositions and methods for management of human papillomavirus-associated cancers. One such method of treating a human papillomavirus-associated cancer in a subject includes administering to the subject a therapeutical...
|
|
WO/2022/173750A1 |
Representative xanthohumol derivatives have been made and have been tested in vivo in mice. Such derivatives have a number of important medicinal benefits, including improving glucose tolerance and decreasing weight gain by increasing en...
|
|
WO/2022/168989A1 |
Provided are a photochromic compound represented by general formula 1, a photochromic compound represented by general formula 2, and a photochromic compound represented by general formula 3. In general formula 1, R100 to R111, X1 and X2 ...
|
|
WO/2022/167695A1 |
The present invention relates to chromen-4-one derivatives, and to associated multi-salts, solvates, and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and p...
|
|
WO/2022/167697A1 |
The present invention relates to chromen-4-one derivatives, and to associated multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatm...
|
|
WO/2022/167696A1 |
The present invention relates to chromen-4-one derivatives, and to associated multi- salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treat...
|
